Evidence map›Paper›PMID 36446995›Full record

ArticleInternational journal of clinical pharmacy2023

A cross-sectional survey exploring the knowledge, experiences and attitudes of Australian pharmacists toward medicinal cannabis.

Zeeta Bawa, Bandana Saini, Danielle McCartney, Miguel Bedoya-Pérez, Andrew J McLachlan, Iain S McGregor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zeeta BawaLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
Bandana SainiSydney Pharmacy School, The University of Sydney, Sydney, NSW, Australia.
Danielle McCartneyLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
Miguel Bedoya-PérezLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia.
Andrew J McLachlanSydney Pharmacy School, The University of Sydney, Sydney, NSW, Australia.
Iain S McGregorLambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, Australia. iain.mcgregor@sydney.edu.au.ORCID http://orcid.org/0000-0002-9307-7159

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAustralian pharmacists currently dispense a wide range of prescription-only cannabis-based medicines. Recent regulatory changes will expand the role of pharmacists, allowing certain low-dose cannabidiol products to be supplied without a prescription in pharmacies. This harmonises Australia with many other countries where cannabidiol products are readily available to consumers.

aimTo examine Australian pharmacists' experience, knowledge and attitudes towards medicinal cannabis and their preparedness to supply over-the-counter low-dose cannabidiol products.

methodWe conducted a cross-sectional study using a 51-item on-line questionnaire that was informed by previous surveys of health professionals and assessed for face validity. Australian pharmacists were recruited to complete the survey between May and December 2021, primarily through professional pharmacy organisations. Pharmacists were included in the final dataset if they completed the demographic characteristics section and at least one additional section of the questionnaire. Data were analysed using descriptive and relational statistical tests.

resultsThere were 272 attempts to complete this survey and 217 responses included in the final dataset. Over half of the respondents (60.0%, 130/217) had dispensed at least one medicinal cannabis prescription during their career and 58.5% (127/217) had received at least one medicinal cannabis enquiry in the last fortnight. Only around half (53.9%, 117/217) felt comfortable supplying medicinal cannabis products and fewer (39.3%, 79/201) were confident discussing cannabis-related enquiries. More than half of the respondents (58.7%, 118/201) supported the provision of low-dose cannabidiol products through pharmacies. Two-thirds (67.8%, 80/118) of respondents achieved relatively low scores (< 60%) in the knowledge component of the survey. Most respondents (94.2%, 178/189) endorsed a need for further training in this area.

conclusionAustralian pharmacists tended to support medicinal cannabis availability and improved access to low-dose cannabidiol products via pharmacies. However, results highlight a need for improved training and education of pharmacists around cannabis-based medicines.

Indexed as

CannabidiolCommunity Pharmacy ServicesMedical MarijuanaAttitudeAustralasian PeopleAustraliaCross-Sectional StudiesHumansNonprescription DrugsPharmacistsSurveys and QuestionnairesCannabidiolMedical MarijuanaNonprescription DrugsCannabidiol (CBD)CannabinoidCannabisCommunity pharmacyMedicinal cannabisPharmacists

Identifiers

PMID36446995
PMCPMC9708126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.